Chronic inflammation of the prostate type IV with respect to risk of prostate cancer

  • Antonio B. Porcaro | drporcaro@yahoo.com Urologic Clinic, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Emanuele Rubilotta Urologic Clinic, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Aldo Petrozziello Geriatric Medicine/Endocrinology, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Claudio Ghimenton Pathology, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Filippo Migliorini Urologic Clinic, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Stefano Zecchini Antoniolli Urologic Clinic, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Vincenzo Lacola Urologic Clinic, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Carmelo Monaco Urologic Clinic, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Pierpaolo Curti Urologic Clinic, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Stefano Cavalleri Urologic Clinic, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Romeo Pianon Urologic Clinic, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Walter Artibani Urologic Clinic, University Hospitals, Ospedale Policlinico and Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Abstract

Background: Chronic inflammatory infiltrate (CII) might be involved in prostate cancer (PCA) and benign hyperplasia (BPH); however, its significance is controversial. Chronic inflammatory prostatitis type IV is the most common non cancer diagnosis in men undergoing biopsy because of suspected PCA. Objective: To evaluate potential associations of coexistent CII and PCA in biopsy specimens after prostate assessment. Design, setting, and participants: Between January 2007 and December 2008, 415 consecutive patients who underwent prostate biopsy were retrospectively evaluated. The investigated variables included Age (years) and PSA (ug/l); moreover, CII+, glandular atrophy (GA+), glandular hyperplasia (GH+), prostate Intraepithelial neoplasm (PIN+), atypical small acinar cell proliferation (ASAP+) and PCA positive cores (P+) were evaluated as categorical and continuous (proportion of positive cores). Outcome measurements and statistical analysis: Associations of CII+ and PCA risk were assessed by statistical methods. Results and limitations: In the patient population, a biopsy core positive for PCA was detected in 34.2% of cases and the rate of high grade PCA (HGPCA: bGS ! 8) resulted 4.82%. CII+ significantly and inversely associated with a positive biopsy core P+ (P < 0.0001; OR = 0.26) and HGPCA (P = 0.0005; OR = 0.05). Moreover, the associations indicated that patients with coexistent CII+ on needle biopsy were 74% less likely to have coexistent PCA than men without CII+ as well as 95% less likely to have HGPCA in the biopsy core than men without coexistent CII+. There were limits in our study which was single centre and included only one dedicated pathologist. Conclusions: There was an inverse association of chronic inflammation of the prostate type IV and risk of PCA; moreover, HGPCA was less likely to be detected in cancers associated with coexistent CII. In prostate microenvironment, prostate chronic inflammation may be protective; however, its role in PCA carcinogenesis remains controversial and needs further research.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2014-09-30
Info
Issue
Section
Reviews - Prostate
Keywords:
Prostate, Prostate cancer, Prostate-specific antigen, Prostate biopsy, Chronic inflammation, Biopsy Gleason score
Statistics
  • Abstract views: 2202

  • PDF: 832
  • SUPPLEMENTARY MATERIAL: 287
How to Cite
Porcaro, A., Rubilotta, E., Petrozziello, A., Ghimenton, C., Migliorini, F., Zecchini Antoniolli, S., Lacola, V., Monaco, C., Curti, P., Cavalleri, S., Pianon, R., & Artibani, W. (2014). Chronic inflammation of the prostate type IV with respect to risk of prostate cancer. Archivio Italiano Di Urologia E Andrologia, 86(3), 208-211. https://doi.org/10.4081/aiua.2014.3.208